These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21310313)

  • 1. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels.
    Choudhry NK; Patrick AR; Glynn RJ; Avorn J
    J Am Coll Cardiol; 2011 Feb; 57(7):784-91. PubMed ID: 21310313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of rosuvastatin therapy JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Hlatky M
    J Am Coll Cardiol; 2011 Feb; 57(7):792-3. PubMed ID: 21310314
    [No Abstract]   [Full Text] [Related]  

  • 3. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
    Michos ED; Blumenthal RS
    J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
    Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
    Hsia J; MacFadyen JG; Monyak J; Ridker PM
    J Am Coll Cardiol; 2011 Apr; 57(16):1666-75. PubMed ID: 21492764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER.
    Slejko JF; Page RL; Sullivan PW
    Curr Med Res Opin; 2010 Oct; 26(10):2485-97. PubMed ID: 20828360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA; Izar MC
    Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
    O'Keefe JH; Carter MD; Lavie CJ; Bell DS
    Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The JUPITER trial: How will it change clinical practice?
    Watson KE
    Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed.
    Perez A; Bartholomew JR
    Cleve Clin J Med; 2010 Mar; 77(3):191-4. PubMed ID: 20200169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
    Ridker PM;
    Circulation; 2003 Nov; 108(19):2292-7. PubMed ID: 14609996
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?
    Sgueglia GA; Crea F
    J Cardiovasc Med (Hagerstown); 2011 Jan; 12(1):66-70. PubMed ID: 21139510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosuvastatin in patients with elevated C-reactive protein.
    Jenny-Avital ER
    N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271275
    [No Abstract]   [Full Text] [Related]  

  • 20. [The JUPITER study: critical review of final results].
    Urbinati S; Romanazzi S; Gambetti S
    G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):28S-32S. PubMed ID: 21298859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.